Department of Radiation Oncology, Julius-Maximilians University, Wuerzburg, Germany.
Radiother Oncol. 2010 Jan;94(1):53-9. doi: 10.1016/j.radonc.2009.12.004. Epub 2010 Jan 14.
To evaluate outcome of radiotherapy for locally recurrent cervical and endometrial cancer.
Nineteen patients were treated for a locally recurrent cervical (n=12) or endometrial (n=7) cancer median 26 months after initial surgery (n=18) or radiotherapy (n=1). The whole pelvis was irradiated with 50Gy conventionally fractionated radiotherapy (n=16). Because of large size of the recurrent cancer (median 4.5 cm) and peripheral location (n=12), stereotactic body radiotherapy (SBRT; median 3 fractions of 5Gy to 65%) was used for local dose escalation instead of (n=16) or combined with (n=3) vaginal brachytherapy.
After median follow-up of 22 months, 3-year overall survival was 34% with systemic progression the leading cause of death (7/10). Median time to systemic progression was 16 months. Three local recurrences resulted in a local control rate of 81% at 3 years. No correlation between survival, systemic or local control and any patient or treatment characteristic was observed. The rate of late toxicity>grade II was 25% at 3 years: two patients developed a grade IV intestino-vaginal fistula and one patient suffered from a grade IV small bowel ileus.
Image-guided SBRT for local dose escalation resulted in high rates of local control but was associated with significant late toxicity.
评估局部复发性宫颈癌和子宫内膜癌的放疗结果。
19 名患者因局部复发性宫颈癌(n=12)或子宫内膜癌(n=7)接受治疗,这些患者在初始手术(n=18)或放疗(n=1)后中位时间为 26 个月。16 名患者采用常规分割放疗,全骨盆照射 50Gy。由于复发性癌症(中位数为 4.5cm)和外周位置(n=12)较大,立体定向体部放疗(SBRT;中位数 3 次 5Gy 至 65%)用于局部剂量升级,而非(n=16)或联合(n=3)阴道近距离放疗。
中位随访 22 个月后,3 年总生存率为 34%,全身进展是死亡的主要原因(7/10)。中位至全身进展时间为 16 个月。3 例局部复发导致 3 年局部控制率为 81%。未观察到生存、全身或局部控制与任何患者或治疗特征之间存在相关性。3 年后晚期毒性>2 级的发生率为 25%:2 例发生 4 级肠-阴道瘘,1 例发生 4 级小肠肠梗阻。
图像引导 SBRT 用于局部剂量升级可获得较高的局部控制率,但与显著的晚期毒性相关。